Year: 2025

ProVen VCT plc (LEI: 21380091P1TTU2Z2AW75)        ProVen Growth and Income VCT plc (LEI: 213800K1RM776QM8XG84)(together the “Companies” and each being a “Company”)         17 November 2025         Publication of Prospectus The Companies announce that they have today published a Prospectus (comprising a Securities Note, Registration Document and Summary) in respect of an offer for subscription to raise up to £30,000,000 in aggregate by way of an issue of new ordinary shares in the Companies (“New Ordinary Shares”), with an over-allotment facility of up to a further £10,000,000 in aggregate (each Company raising a maximum of £20,000,000 including the over-allotment facility), payable in full in cash on application (the “Offer”). The Offer opens on 17 November 2025 and will close not later than 12 p.m....

ProVen VCT plc (LEI: 21380091P1TTU2Z2AW75)        ProVen Growth and Income VCT plc (LEI: 213800K1RM776QM8XG84)(together the “Companies” and each being a “Company”)         17 November 2025         Publication of Prospectus The Companies announce that they have today published a Prospectus (comprising a Securities Note, Registration Document and Summary) in respect of an offer for subscription to raise up to £30,000,000 in aggregate by way of an issue of new ordinary shares in the Companies (“New Ordinary Shares”), with an over-allotment facility of up to a further £10,000,000 in aggregate (each Company raising a maximum of £20,000,000 including the over-allotment facility), payable in full in cash on application (the “Offer”). The Offer opens on 17 November 2025 and will close not later than 12 p.m....

System of Care to Advance Care for the Most Commonly Inherited Heart Disease SOUTH SAN FRANCISCO, Calif., Nov. 17, 2025 (GLOBE NEWSWIRE) —  Cytokinetics, Inc. (Nasdaq: CYTK) today announced its support of a three-year initiative led by the American Heart Association to address disparities in access to care, diagnosis, and treatment for people living with hypertrophic cardiomyopathy (HCM), a chronic and often underdiagnosed heart disease that affects hundreds of thousands of individuals across the United States. As a supporter of this multi-stakeholder undertaking, Cytokinetics will contribute its longstanding commitment to the HCM community to help close prevailing gaps between evidence, guidelines, implementation, and equity in healthcare delivery for HCM. “Too many patients living with HCM face a lack of awareness about their...

Company Posts Strong Revenue Momentum, Global Licensing Pipeline and Real‑World Asset Tokenization LeadershipQ3-25 Revenue rose 148% YOY to $2.9M DVLT Discusses New Global Business Pipeline Raises FY 2025 Revenue Guidance to a low end of $30M, Raises 2026 Guidance to $200M Management Hosting a Live Webcast at 8:30 a.m. ET; Information BelowPHILADELPHIA, Nov. 17, 2025 (GLOBE NEWSWIRE) — via IBN – Datavault AI Inc. (Nasdaq: DVLT), a leader in data monetization, credentialing, and digital engagement technologies, today provided a corporate update that includes substantial commercial advances, expanding global partnerships, and a deepening pipeline of licensing contracts across real‑world asset (RWA) tokenization. Q3-2025 Financial Highlights Revenue for the third quarter ended Sept. 30, 2025, rose 148% YOY to $2.9 million, and...

Strategic Distribution Ahead of Value-Unlocking Carve-Out KUALA LUMPUR, Malaysia, Nov. 17, 2025 (GLOBE NEWSWIRE) — VCI Global Limited (NASDAQ: VCIG) (“VCI Global” or the “Company”) today announced that its Board of Directors has approved a special dividend in the form of 10% of the share capital of its cybersecurity and AI subsidiary, V Gallant Limited (“V Gallant”), to be distributed on a pro rata basis to all VCIG shareholders. The distribution is expected to broaden shareholder participation in V Gallant while reducing corporate concentration, thereby strengthening trading liquidity and enhancing long-term alignment across both entities. It marks the first step in VCI Global’s value-unlocking strategy as V Gallant progresses toward its planned Nasdaq carve-out IPO, which management estimates could fall within a nine-figure valuation...

The 3D, AI Powered Technology Screens 25,000 People Per Hour—Without Stopping Them Tel Aviv, Israel, Nov. 17, 2025 (GLOBE NEWSWIRE) — Jeffs’ Brands Ltd (“Jeffs’ Brands” or the “Company”) (Nasdaq: JFBR, JFBRW), a data-driven e-commerce company operating on the Amazon Marketplace, announced today that Jeffs’ Brands Holdings Inc., its’ wholly owned subsidiary (“Jeffs’ Brands Holdings” or the “Subsidiary”) has entered into a non-binding Memorandum of Understanding (“MOU”) with Scanary Ltd. (“Scanary”), an Israeli deep-tech developer of  3D imaging, electromagnetic, AI-powered threat detection systems, which transaction would mark a strategic pivot into the global homeland-security sector. According to the MOU, Scanary would grant Jeffs’ Brands Holdings, upon the entry into a definitive agreement, the right to market and distribute...